Workshop: An ANTIDotE for tick borne diseases, 3rd of June 2016 in Berlin  

The ANTIDotE workshop was a great success! Researches from academic, governmental and commercial institutes from Europe, North America and Africa attended the workshop. We want to thank all participants for their presence and input which resulted in a vigorous day with many discussions.                           



ANti-tick vaccines to prevent TIck-borne Diseases in Europe.

EC flag

ANTIDotE is a consortium of 7 European research institutes funded by the European Commssion to investigate anti-tick vaccines. Our objective is to identify and characterize tick salivary gland proteins involved in tick feeding and tick-borne pathogen transmission, and to use this knowledge to develop and assess anti-tick vaccines to prevent multiple human tick-borne diseases.


 The Group

The ANTIDotE consortium consists of 7 European participants, and an advisory board with 7 partners with different backgrounds and networks. This enables ANTIDotE to achieve its groundbreaking objectives.

For more information on the participants see the participants section of this website. The advisory board consists of Yale University (Yale), the Research Institite for Wildlife Health in Europe (Artemis), the Friedrich-Loeffler Institute (FLI), the National Institute of Public Health from the Czech Republic (NIPH CZ), Nationa Public Health Institute of Slovenia (NPHI SL), Center for Tick-borne Diseases in Hungary (CTB) and Theo Schetters (current protActivity and former Merck, Sharp & Dohme (MSD).

This work is supported by funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No. 602272 (project ANTIDotE)